73-OR: Clonal Hematopoiesis of Indeterminate Potential (CHIP), Glycemic Traits, and Type 2 Diabetes (T2D) Risk
Authors: TOBIAS DEIRDRE K. , MANNING ALISA , WESSEL JENNIFER , WESTERMAN KENNETH E. , RAGHAVAN SRIDHARAN , RAFFIELD LAURA , DUPUIS JOSEE , BICK ALEXANDER , WU PEITAO , DICORPO DANIEL A. , PSATY BRUCE M. , MORRISON ALANNA C. , RAMACHANDRAN VASAN S. , CUPPLES L. ADRIENNE , LANGE LESLIE , CORREA ADOLFO , KOOPERBERG CHARLES L. , TINKER LESLEY F. , HOWARD BARBARA V. , REINER ALEX , ROTTER JEROME I. , COLLINS JASON M. , MEIGS JAMES B. , MANSON JOANN E. 
Published: June 2021

Objective: CHIP is an aging-related accumulation of somatic mutations in hematopoietic stem cells, leading to clonal expansion. CHIP presence has been implicated in elevated atherosclerotic heart disease (CHD) and all-cause mortality, but its association with incident T2D is unknown. We hypothesize CHIP is adversely associated with glycemic traits and T2D.
Methods: We included N=16,054 participants in NHLBI Trans-omics for Precision Medicine (TOPMed), without prior T2D or chronic disease at blood draw. CHIP was derived from blood DNA whole genome sequencing using the GATK MuTECT2 somatic variant caller in pre-specified leukemogenic driver mutations. We estimated CHIP overall and candidate CHD-related mutations (DNMT3A, TET2, ASXL1, JAK2) in relation to baseline glycemic traits (fasting glucose, insulin, HOMA-IR) with linear regression. We evaluated CHIP with incident T2D using Cox regression to estimate hazard ratios and 95% confidence intervals (HR [CI]). Models adjusted for age, sex, body mass index, smoking, and family history of T2D. We combined cohort-specific estimates via random effects meta-analysis with inverse variance weighting.
Results: CHIP was present in n=1,088 (7%) of participants. We observed 1,853 incident T2D cases over mean=10y follow-up. Baseline fasting glucose, insulin, and HOMA-IR did not differ by CHIP status. Participants with CHIP had a higher risk of incident T2D than those without CHIP (1.27 [1.08, 1.51]), with a significant dose-response per additional CHIP mutation (p-trend=0.005). Analyses of CHD-related CHIP vs. no CHIP mutations suggested associations with higher T2D risk for DNMT3A (1.21 [0.97, 1.51]) and TET2 (1.35 [0.93, 1.97]), and ASXL1 (1.92 [0.71, 5.13]), although analyses of individual mutations were underpowered.
Conclusions: CHIP is associated with a higher T2D risk. This relationship may be unrelated to baseline glycemic traits. CHIP-T2D association suggests a potential role for CHD-related pathology in T2D.

Disclosure
D. K. Tobias: None. D. A. Dicorpo: None. B. M. Psaty: None. A. C. Morrison: None. V. S. Ramachandran: None. L. Cupples: None. L. Lange: None. A. Correa: None. C. L. Kooperberg: None. L. F. Tinker: None. B. V. Howard: None. A. Manning: Employee; Spouse/Partner; Emulate, Inc, Stock/Shareholder; Spouse/Partner; Invitae. A. Reiner: None. J. I. Rotter: None. J. M. Collins: None. J. B. Meigs: Consultant; Self; Quest Diagnostics. J. E. Manson: None. J. Wessel: Employee; Spouse/Partner; Eli Lilly and Company. K. E. Westerman: None. S. Raghavan: None. L. Raffield: None. J. Dupuis: None. A. Bick: None. P. Wu: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (U01DK078616 to J.B.M., J.D., D.A.D., P.W.), (U01DK105554 to J.D., D.A.D.)